Neotherix (York UK) has developed the EktoTherix™ bioresorbable scaffold material that assists patient tissue repair and regeneration, with an initial target clinical application of non-melanoma skin cancers (NMSC) with further indications to follow. A patch of the material is used following excision of the basal or squamous carcinoma by the clinician, and this rapidly allows the wound space to be filled with (and then covered by) the patients’ own skin cells. This TSB funded project will continue the development of the product towards full commercialisation, with further development of the product registration package leading to a clinical evaluation involving a small number of patients. The team will also complete a health economics evaluation prior to launching the product within the UK and EU market in 2013/2014. The estimated global market for this product for NMSC alone is £867m pa.